Recently, Opaganib (ABC294640, 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl) amide, or trade name Yeliva®) [133,196], a specific SphK2 inhibitor, has been listed to start global randomised phase II/III clinical trials for COVID-19 patients (ClinicalTrials.gov Identifier: NCT04467840), and a United States randomised phase II study (ClinicalTrials.gov Identifier: NCT04414618). The gene discussed is SPHK2; the disease is COVID-19.